First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 18, 2025.

By I. Edwards HealthDay Reporter

FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies.

Eli Lilly said its experimental drug, orforglipron, helped people with type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to market, The Wall Street Journal said.

GLP-1 drugs, such as Ozempic and Wegovy, are popular for helping people manage diabetes and lose weight. But right now, they are only available as injections.

Doctors and patients have been hoping for a pill version that would be easier to take.

“It really gives us an opportunity to reach many more patients than you can reach with an injectable,” Jeffrey Emmick, senior vice president of product development at Lilly Cardiometabolic Health, told The Wall Street Journal.

Some people don’t like injections, and injectable drugs often need to be kept cold. The pill version could help more people around the world who don’t have easy access to refrigeration.

It may also be easier to produce in large amounts. Lilly’s injectable GLP-1 drug went into shortage shortly after it was released.

In the new study, orforglipron was tested for 40 weeks in adults with type 2 diabetes. People who took the highest dose lost an average of 16 pounds, or about 7.9% of their body weight. The most common side effects were stomach-related and were mostly mild or moderate, Lilly said.

The company plans to submit the pill for approval as a weight-loss treatment by the end of 2025 and for diabetes treatment in 2026.

The drug works by targeting the GLP-1 hormone, which helps regulate blood sugar and reduce appetite. Unlike other GLP-1 drugs that are made from large molecules, orforglipron is a small molecule. That means the body may absorb it more easily, The Wall Street Journal reported.

Other companies, including Novo Nordisk and Pfizer, are also developing GLP-1 pills. Experts expect the obesity drug market to grow to more than $100 billion by the end of the decade.

For more information, see What is orforglipron?

Sources

  • The Wall Street Journal, April 17, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-19 06:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords